# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-25-006010
Filing Date
2025-04-30
Accepted
2025-04-30 16:30:32
Documents
19
Period of Report
2025-06-26

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | plx-20250626xdef14a.htm iXBRL | DEF 14A | 758124
2 | GRAPHIC | plx-20250626xdef14a_a003.jpg | GRAPHIC | 8004
3 | GRAPHIC | plx-20250626xdef14a_a004.jpg | GRAPHIC | 3343
4 | GRAPHIC | plx-20250626xdef14a_bg001.jpg | GRAPHIC | 106780
5 | GRAPHIC | plx-20250626xdef14a_bg002.jpg | GRAPHIC | 170278
| Complete submission text file | 0001558370-25-006010.txt |  | 3167740

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | EX-101.SCH | plx-20250626.xsd | EX-101.SCH | 3801
7 | EX-101.LAB | plx-20250626_lab.xml | EX-101.LAB | 3686
8 | EX-101.PRE | plx-20250626_pre.xml | EX-101.PRE | 3933
21 | EXTRACTED XBRL INSTANCE DOCUMENT | plx-20250626xdef14a_htm.xml | XML | 740014

Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 25895942
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)